Filter
1133
Text search:
drug
susceptibility
Featured
152
273
Language
Document type
581
211
200
59
34
19
15
10
2
1
1
Countries
59
42
32
30
28
25
24
23
19
18
18
16
15
14
14
14
14
10
9
9
9
8
7
7
6
6
6
6
6
5
5
5
5
4
4
4
4
4
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
363
137
58
25
21
19
15
Toolboxes
338
181
57
43
40
38
27
22
18
14
14
14
12
11
11
11
10
10
7
7
5
4
3
2
Antimicrobial Resistance and Infection Control 2014,3 :31
Progress in diagnosis: Akey in overcoming the MDR-TB crisis.
The expanse-TV project progress and impact brief.
Moving avidence into action
This document is part of a series of briefs for health program managers interested in implementing evidence-based programs. With a special emphasis on underutilized interventions, they present evidence on programs that work and provide guidance and resources for replicat
...
Accessed November 2017
Division of Global Migration and Quarantine
April 16, 2012
A manual for programme managers.
БОРЬБА С ТУБЕРКУЛЕЗОМ В ТЮРЬМАХ
Руководство для руководителей программ
Epidemiology, Control, and Financing
4–15 February 2013
This guide includes information relevant for tuberculosis (TB) program and laboratory managers, as well as Ministry of Health officials across disease programs interested in establishing integrated solutions for specimen referral. Though TB-focused in name, it offers integration-oriented assessment,
...
A large meta-analysis of observational studies that provided the basis for the recent makeover of global recommendations for multidrug-resistant tuberculosis (MDR-TB) treatment shows that newer and repurposed drugs produced better outcomes and fewer deaths than older treatments.
The meta-analysis
...
6th edition
Patients with retreatment tuberculosis (TB) represent those
who have been treated previously for onemonth ormorewith
anti-TB drugs and who have been diagnosed once again with
the disease.These patientsmainly include relapses, treatment
after failure, or loss to follow-up on a first-line treatmen
...
